Clinical validation of a plasma <i>p</i> ‐tau217 immunoassay and evaluation of the impact of kidney function

This plasma p -tau217 assay has high concordance with amyloid PET and may aid in the diagnostic workup of AD. Furthermore, quantification of p -tau217 using this assay was not impacted by reduced eGFR status, suggesting it can provide reliable results in individuals with renal impairment.